GAP43 and early-onset autosomal dominant Alzheimer disease: As increased CSF GAP-43 concentration was associated to Alzheimer’s disease neuropathology and correlated with cognitive decline, it could be useful as an outcome marker in clinical trials for novel Alzheimer’s disease therapeutics.